Catherine Weiss, PhD

Efficacy and Safety of Brexpiprazole in Patients With Schizophrenia Presenting With Severe Psychotic Symptoms During an Acute Exacerbation

Background: Schizophrenia is a chronic, disabling and progressive disease, with heterogenous symptoms and disease course between individuals. Severity of symptoms has been shown to be a s...

Catherine Weiss , PhD;

Stine Rasmussen Meehan , PhD;

Nicole Meade , PhD;

Lily Shi , MSc;

03/01/2019

Examining Depressive Symptoms Across Diagnostic and Statistical Manual Indications: Treatment Effects of Brexpiprazole in Patients With Major Depressive Disorder and Schizophrenia

Background: The NIMH Research Domain Criteria (RDoC) framework could be used to recategorize symptoms across the established DSM criteria for neuropsychiatric disorder indications. This p...

Catherine Weiss , PhD;

Stine Rasmussen Meehan , PhD;

Malaak Brubaker , PhD;

Dalei Chen , PhD;

Ross Baker , PhD, MBA;

Ruth Duffy , PhD;

10/08/2020

Efficacy of Adjunctive Brexpiprazole in Adults With MDD: Improvement of Patient Engagement Based on Selected Items From the Inventory of Depressive Symptomatology Self-Report (IDS-SR) Scale

Objective: These post-hoc analyses used relevant items from the IDS-SR to explore whether treatment with adjunctive brexpiprazole in patients with MDD has potential to improve a new conce...

Anne Pedersen , MSc;

Klaus Groes Larsen , PhD;

Anna-Greta Nylander , PhD;

Catherine Weiss , PhD;

Stine Rasmussen Meehan , PhD;

Michael Thase , MD;

Zahinoor Ismail , MD;

Dalei Chen , PhD;

Ross Baker , PhD, MBA;

Roger McIntyre , MD, FRCPC;

11/22/2019